The results of a 24 month controlled, prospective study of relapsing MS patients at risk for PML who switched from long term natalizumab to teriflunomide

Authors

• Stanley Cohan, Providence Multiple Sclerosis Center, USA.Follow

Document Type

Presentation

Publication Date

2018

Area of Special Interest

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences